Abbott Laboratories (NYSE:ABT) Price Target Raised to $112.00

Abbott Laboratories (NYSE:ABT) had its price target raised by Citigroup from $108.00 to $112.00 in a research report sent to investors on Friday,Benzinga reports. Citigroup currently has a buy rating on the healthcare product maker’s stock.

A number of other research analysts also recently weighed in on the company. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday. Stifel Nicolaus lowered their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. UBS Group dropped their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, Oppenheimer cut their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Abbott Laboratories Price Performance

Shares of ABT opened at $100.71 on Friday. The firm has a fifty day simple moving average of $89.89 and a two-hundred day simple moving average of $102.01. The firm has a market cap of $175.41 billion, a PE ratio of 32.59, a P/E/G ratio of 1.73 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the business posted $1.26 EPS. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by company insiders.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Freemont Management S.A. lifted its position in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans raised its stake in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the period. Net Worth Advisory Group bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $1,366,000. Finally, Mn Services Vermogensbeheer B.V. lifted its holdings in Abbott Laboratories by 2.1% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock worth $84,163,000 after purchasing an additional 13,543 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.